Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR845 in Osteoarthritis of the Hip or Knee
NCT02944448Phase 2Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Sep 2016
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing CR845 with Placebo (2 arms). Primary endpoint: Change From Baseline at Week 8 With Respect to the Weekly Mean of the Daily 24-hour Pain Intensity for the Index Joint as Measured by the Numeric Rating Scale. Started Sep 2016; status: completed.
02
Drugs
difelikefalin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02944448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944448.